These two IL-17A promoter SNPs can possibly be utilized as potential biomarkers in the absence of an MT EGFR in LUAD patients who smoke, as well as a cancer aggressiveness predictor for WT EGFR LUAD patients. Here, IL17A is linked to cancer.